RF Vapor Ablation

DEVICE4 trials

Sponsors

Aqua Medical, Inc.

Conditions

Diabetes Mellitus Type 2Diabetes Mellitus, Type 2Type-2 Diabetes Mellitus

Unknown Phase

Study of Duodenal Mucosal RF Vapor Ablation in Subjects With Type-2 Diabetes Mellitus

RecruitingNCT05887635

Aqua Medical, Inc.Diabetes Mellitus Type 2

Start: 2023-09-02End: 2026-06-30Target: 40Updated: 2024-10-24

Safety, Tolerability, and Effectiveness of Duodenal Mucosal RF Vapor Ablation for Insulin Elimination in Type-2 Diabetes

Active, not recruitingNCT06655740

Aqua Medical, Inc.Diabetes Mellitus, Type 2

Start: 2024-10-01End: 2027-07-31Target: 16Updated: 2025-11-07

RF Vapor Ablation Retreatment of Duodenal Mucosa in Non-responders With Type-2 Diabetes Mellitus

Active, not recruitingNCT06724822

Aqua Medical, Inc.Diabetes Mellitus, Type 2

Start: 2024-11-14End: 2027-06-30Target: 12Updated: 2025-11-06

A U.S. Pilot Human Investigation of RadiofrEquency Vapor Ablation System to Evaluate Safety, TOleRability, and Effectiveness for Proximal Intestinal Mucosal Ablation in Patients With Type 2 Diabetes Mellitus (RESTORE-1 Study)

RecruitingNCT07355270

Aqua Medical, Inc.Type-2 Diabetes Mellitus

Start: 2026-04-01End: 2027-03-31Target: 20Updated: 2026-04-30

Related Papers

895-P: Proximal Intestinal Mucosal Ablation (PIMA) Eliminates the Need for Exogenous Insulin in Type 2 Diabetes—Initial STEAM-IE Trial Results

Diabetes2025-06-13